Kidney Disease & Nephrology Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia

This Phase 3 trial is studying whether DDAVP can help prevent dangerous rapid increases in sodium levels in patients with severe hyponatremia who are in intensive care units. If DDAVP proves effective, it could make treatment safer by lowering the risk of complications related to sodium imbalance. The study is currently recruiting 260 patients in France and aims to improve outcomes for critically ill patients with this condition.

A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China

This Phase 4 study is testing semaglutide injections in adults with both type 2 diabetes and chronic kidney disease to see how the drug affects kidney and heart health. The goal is to find treatments that better protect these vital organs and improve quality of life. Recruitment is ongoing in China, and the study will follow participants for up to three years, offering important data on long-term effects.

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

This Phase 4 trial evaluates the safety and effectiveness of dapagliflozin, a pill taken by mouth, in adults with chronic kidney disease in China. The medication may help slow down the worsening of kidney function and reduce related health problems. The study is active but not currently recruiting, taking place at various sites across China with broad eligibility for adult patients.

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

This Phase 2 trial is exploring how exercise training combined with sodium bicarbonate treatment can improve blood flow and exercise ability in people with chronic kidney disease. The research could lead to new ways to enhance physical health and quality of life for patients. The study is enrolling 156 participants in the United States and focuses on understanding the body's responses to these treatments during exercise.

A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease

This Phase 2 trial is testing Guominkang, a traditional herbal medicine, in adults with diabetic kidney disease to see if it can safely reduce kidney damage by lowering protein in the urine. This treatment could offer an additional option for managing kidney health in people with diabetes. The study is recruiting in China and includes 12 weeks of treatment with follow-up monitoring.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.